Recent Advancements in the Application of Circulating Tumor DNA as Biomarkers for Early Detection of Cancers

ACS Biomaterials Science & Engineering, Journal Year: 2024, Volume and Issue: 10(8), P. 4740 - 4756

Published: July 1, 2024

Early detection of cancer is vital for increasing patient survivability chances. The three major techniques used to diagnose cancers are instrumental examination, tissue biopsy, and tumor biomarker detection. Circulating DNA (ctDNA) has gained much attention in recent years due advantages over traditional technology, such as high sensitivity, specificity, noninvasive nature. Through the mechanism apoptosis, necrosis, circulating exosome release cells, ctDNA can spread throughout circulatory system carry modifications methylations, mutations, gene rearrangements, microsatellite instability. Traditional gene-detection technology struggles achieve real-time, low-cost, portable measurement, whereas electrochemical biosensors offer low cost, specificity alongside portability ctDNA. Therefore, this review focuses on describing advancements biomarkers various types biosensor developments noninvasive, rapid Further review, sensors also discussed regards their selections probes receptors based electrode surface recognition elements.

Language: Английский

---

Circulating tumor DNA methylation detection as biomarker and its application in tumor liquid biopsy: advances and challenges

MedComm, Journal Year: 2024, Volume and Issue: 5(11)

Published: Nov. 1, 2024

Abstract Circulating tumor DNA (ctDNA) methylation, an innovative liquid biopsy biomarker, has emerged as a promising tool in early cancer diagnosis, monitoring, and prognosis prediction. As noninvasive approach, overcomes the limitations of traditional tissue biopsy. Among various biomarkers, ctDNA methylation garnered significant attention due to its high specificity detection capability across diverse types. Despite immense potential, clinical application faces substantial challenges pertaining sensitivity, specificity, standardization. In this review, we begin by introducing basic biology common techniques methylation. We then explore recent advancements faced biopsies. This includes progress screening identification molecular subtypes, monitoring recurrence minimal residual disease (MRD), prediction treatment response prognosis, assessment burden, determination origin. Finally, discuss future perspectives applications. comprehensive overview underscores vital role enhancing diagnostic accuracy, personalizing treatments, effectively progression, providing valuable insights for research practice.

Language: Английский

---

Oral Cancer: Recent Breakthroughs in Pathology and Therapeutic Approaches

Oral Oncology Reports, Journal Year: 2024, Volume and Issue: unknown, P. 100678 - 100678

Published: Oct. 1, 2024

Language: Английский

---

Salvianolic acid B from Salvia miltiorrhiza bunge: A potential antitumor agent

Frontiers in Pharmacology, Journal Year: 2022, Volume and Issue: 13

Published: Oct. 25, 2022

Salvia miltiorrhiza Bunge (Lamiaceae) is a perennial herb widely found in China since ancient times with high economic and medicinal value. Salvianolic acid B (Sal-B) an important natural product derived from this review summarizes the anticancer activity of Sal-B. Sal-B inhibits tumor growth metastasis by targeting multiple cell signaling pathways. This aims to experimental studies describe possible mechanisms confirm its potential as therapeutic drug.

Language: Английский

---

ctDNA as an Adjunct to Posttreatment PET for Head and Neck Cancer Recurrence Risk Assessment

Otolaryngology, Journal Year: 2024, Volume and Issue: 171(2), P. 439 - 444

Published: April 9, 2024

Abstract Objective Circulating tumor DNA (ctDNA) detection is an emerging technique that identifies minimal residual disease in patients with solid tumors. ctDNA can act as adjunct method to help overcome the limitations of positron emission tomography (PET) and select who are at high risk for recurrence. Study Design Retrospective Single Institutional Study. Setting University Hospital Setting. Methods Twenty‐nine underwent definitive treatment squamous cell carcinoma head neck (HNSCC) from 8/2021 01/2023 had levels analyzed 1 3, 6, 9, 12 months after treatment. A personalized, tumor‐informed, multiplex polymerase chain reaction (PCR) next‐generation sequencing (NGS) assay was used detect levels. The primary outcome recurrence‐free probability (RFP), secondary outcomes were overall survival (OS), sensitivity, specificity, test's negative (NPV) positive predictive values (PPV). Results median age 65 years (interquartile range: 56‐69), majority being males (n = 22, 76%). sites larynx 12), oropharynx 10), oral cavity 6). Posttreatment detected 7 patients, all whom associated a higher recurrence (hazard ratio: 9.94, 95% confidence interval: 1.56‐63.3, P .015). identified 100% specificity 78% sensitivity. NPV PPV 91% 100%. PET sensitivity but only 68% 86% NPV, 54% PPV. Conclusion Based on our data, be excellent test posttreatment guide physicians cases where results inconclusive difficult interpret.

Language: Английский

---

Evolution of testing for the diagnosis of human papillomavirus (HPV) status in head and neck squamous cell carcinoma: Where from and where to?

Oral Oncology, Journal Year: 2025, Volume and Issue: 162, P. 107208 - 107208

Published: Feb. 2, 2025

Language: Английский

---

Circulating tumor DNA in human papillomavirus-associated oropharyngeal cancer management: A systematic review

Oral Oncology, Journal Year: 2025, Volume and Issue: 164, P. 107262 - 107262

Published: April 1, 2025

Language: Английский

---

Emerging Roles of Circulating Tumor DNA for Increased Precision and Personalization in Radiation Oncology

Seminars in Radiation Oncology, Journal Year: 2023, Volume and Issue: 33(3), P. 262 - 278

Published: June 16, 2023

Language: Английский

---

Mapping the Potential of Microfluidics in Early Diagnosis and Personalized Treatment of Head and Neck Cancers

Cancers, Journal Year: 2023, Volume and Issue: 15(15), P. 3894 - 3894

Published: July 31, 2023

Head and neck cancers (HNCs) account for ~4% of all in North America encompass affecting the oral cavity, pharynx, larynx, sinuses, nasal salivary glands. The anatomical complexity head region, characterized by highly perfused innervated structures, presents challenges early diagnosis treatment these cancers. utilization sub-microliter volumes unique phenomenon associated with microscale fluid dynamics have facilitated development microfluidic platforms studying complex biological systems. advent on-chip microfluidics has significantly impacted strategies HNC. Sensor-based point-of-care devices improved detection monitoring cancer biomarkers using specimens like saliva, urine, blood, serum. Additionally, tumor-on-a-chip allowed creation patient-specific models on a chip, enabling personalized treatments through high-throughput screening drugs. In this review, we first focus how enable an enhanced, functional drug process targeted HNCs. We then discuss current advances biomarker sensing detection, followed modeling HNC to evaluate response. Finally, address practical that hinder clinical translation advances.

Language: Английский

---

Circulating tumor-tissue modified HPV DNA testing in the clinical evaluation of patients at risk for HPV-positive oropharynx cancer: The IDEA-HPV study

Oral Oncology, Journal Year: 2023, Volume and Issue: 147, P. 106584 - 106584

Published: Oct. 12, 2023

Language: Английский

---